The North America organ preservation solution market was valued at US$ 1,23,239.05 thousand in 2023 and is expected to reach US$ 2,26,118.82 thousand by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.
Rising Need for Organ Transplantation Fuels North America Organ Preservation Solution Market
Several chronic diseases are known to damage the functioning of the heart, lungs, liver, kidney, and other organs. A poor diet contributes to the development of renal and hepatic illnesses, which can also lead to organ failure. For instance, around 10% of the global population is impacted by chronic kidney disease. According to the US Department of Health & Human Services, more than 1 in 7 (i.e., ~15% or ~37 thousand adults) are estimated to have chronic kidney disease in the US. Further, excessive alcohol consumption leads to liver cirrhosis, resulting in the need for a liver transplant. The Scientific Registry of Transplant Recipients (SRTR) reports that irrespective of the success of medical treatments for heart failure, the number of candidates eligible for new heart transplants continues to rise. The COVID-19 pandemic had some impact on new listings. After a plateau from 2018 through 2020 and a slight decrease in 2020 (from 4,087 in 2019 to 4,000 in 2020), the number of new heart failure cases increased to 4,373 in 2021. Transplantation surgeries are becoming more common worldwide. In 2023, the United Network for Organ Sharing reported a record of more than 46,000 organ transplants in the US, marking an increase of over 8.7% from 2022. Additionally, the country crossed the mark of 27,000 kidney transplants for the first time in its history. Patients who are on the organ waiting list typically suffer from end-stage organ disease, which significantly affects their quality of life and may indicate that they are nearing the end of their life. The rising number of individuals with end-stage organ failure triggers the need for timely organ transplantation. Due to advancements in transplantation techniques, more such people are now eligible for organ transplants. Organ preservation solutions are used to maintain the viability and function of organs for a certain period, allowing for their transport and subsequent transplantation into a recipient. The success of organ transplantation is primarily determined by organ preservation, surgery, immunotherapy, and post-operative care. Thus, a rising demand for organ transplantation drives the organ preservation solution market toward growth.
North America Organ Preservation Solution Market Overview
The North America organ preservation solution market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging number of organ transplants are the factors benefiting the organ preservation solution market in this region. The US is the largest organ preservation solution market across the world and is estimated to dominate the global market during the forecast period. The US market growth is attributed to the rising chronic kidney diseases (CKD) prevalence and the increasing geriatric population in the US. According to the National Chronic Kidney Disease fact sheet, ~37 thousand people in the US were suffering from chronic kidney diseases in 2021.
In June 2024, the American Kidney Fund, Inc. reported that up to 37 thousand Americans have kidney disease, and ~808,000 Americans are affected by kidney failure. More than 557,000 Americans are undergoing dialysis treatment. The prevalence of kidney disease is rising and currently affects over 1 in 7 (or 14%) of American adults. In 2021, around 135,000 Americans were newly diagnosed with kidney failure. Also, 9 out of 10 people affected by kidney disease are unaware they have it, and 1 in 3 of people with severely reduced kidney function are also unaware they have kidney disease. Furthermore, as per the same source stated that more than 250,000 Americans have undergone kidney transplants, and there are over 93,000 Americans on the kidney transplant waiting list. In 2023, only 27,332 people received kidney transplants, with 6,290 of those from living donors. The rising number of approvals from the US Food and Drug Administration (FDA) and the presence of market players in the country boost the US organ preservation solution market growth. In April 2022, TransMedics Group, Inc. announced that it received premarket FDA approval for its OCS Heart System, which can be used with organs from donors after circulatory death (DCD). The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death (DCD) hearts. Thus, the rising need for organ transplantation drives the organ preservation solutions market in the US. Organ preservation solution manufacturers in the US launch devices used for organ transportation. In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system, BAROguard. The system combines Paragonix's advanced hypothermic preservation technology with automated continuous and active airway pressure control. This ensures that an optimal temperature range and a clinically recommended inflation pressure range for donor lungs are maintained throughout the journey from the donor to the recipient patient. This novel combination of advanced technologies reinforces the company's ongoing commitment to improving and redefining the standard of care within transplant medicine.
North America Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)
North America Organ Preservation Solution Market Segmentation
The North America organ preservation solution market is categorized into product, application, type, end user, and country.
Based on product, the North America organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held the largest market share in 2023.
In terms of application, the North America organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.
By type, the North America organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.
Based on end user, the North America organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.
By country, the North America organ preservation solution market is segmented into the US, Canada, and Mexico. The US dominated the North America organ preservation solution market share in 2023.
Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, 21ST Century Medicine, and Bridge to Life Ltd., are among the leading companies operating in the North America organ preservation solution market.